The Journal of Urology

The Journal of Urology The official journal of the AUA, The Journal of Urology® is the most widely read and highly cited p

04/10/2026

Can prostate biopsy be just as accurate—with fewer needles and fewer complications?

In biopsy‑naïve men with MRI‑visible lesions, targeted and perilesional biopsy matched cancer detection rates while significantly reducing bleeding, pain, procedure time, and cost compared with standard combined biopsy.

🔗 Click to read more: https://bit.ly/4v1fvdB

04/09/2026

The May 2026 Journal of Urology® is here! Stay current with cutting-edge research, clinical insights and global literature in the most cited journal in the field!

🔗 Read now: https://bit.ly/41UycT1

04/09/2026

Could prostate cancer treatment deliver strong disease control without sacrificing sexual health?

Enzalutamide monotherapy improved key long‑term outcomes and better preserved sexual function compared with leuprolide alone, supporting a promising treatment option for patients with high‑risk biochemical recurrence.

🔗 Click to read more: https://bit.ly/4cSfodY

04/07/2026

The author of this editorial emphasizes that ultrasound‑derived relative renal volume shows strong agreement with nuclear scintigraphy in a highly selected VUR population, but cautions that it should be viewed as a helpful adjunct rather than a replacement, noting limits in generalizability, missed cases of impaired function, and the need for further validation before broader clinical adoption.

🔗 Click to read more: https://bit.ly/4sKMGRq

04/06/2026

Can kidney function be assessed without radiation or added cost?

In children with unilateral vesicoureteral reflux, ultrasound‑measured relative renal volume closely predicted differential renal function—pointing to a safe, accurate alternative that could reduce the need for nuclear imaging.

🔗 Click to read more: https://bit.ly/4m2h6Ml

04/03/2026

The authors of this editorial caution that growing use of intraoperative 0.05% chlorhexidine in hydrophilic pe**le prosthesis surgery may be misguided, noting consistent signals of higher infection risk and arguing that even small increases in infection outweigh any perceived convenience or cost savings.

🔗 Click to read more: https://bit.ly/4m86jAq

04/01/2026

This editorial examines where ProVee fits among minimally invasive BPH therapies, acknowledging comparable symptom improvement and sexual function preservation while emphasizing unanswered questions about long‑term outcomes.

🔗 Click to read more: https://bit.ly/4dhflbT

03/31/2026

What if effective BPH relief required no cutting, no catheter, and no tradeoffs?

A novel prostatic urethral stent delivered durable symptom improvement through 12 months with no serious adverse events and preserved sexual function—pointing to a new ultra‑minimally invasive treatment option.

🔗 Click to read more: https://bit.ly/4cfxypc

03/26/2026

What if a commonly used infection‑prevention step is actually raising risk?

In a 14‑institution study of 2,150 cases, intraoperative 0.05% chlorhexidine gluconate use with hydrophilic inflatable pe**le prostheses was linked to higher infection rates (4.6% vs 2.1%)—suggesting caution until further prospective data are available.

🔗 Click to read more: https://bit.ly/4rUU6Ag

03/23/2026

Can what you eat after diagnosis change prostate cancer outcomes?

This new systematic review suggests that healthier diets and lifestyles—plant‑forward eating, regular physical activity, not smoking, and maintaining a healthy weight—may help reduce prostate cancer progression and overall mortality, supporting lifestyle guidance as part of survivorship care.

🔗 Click to read more: https://bit.ly/4d1NA6Y

03/19/2026

📊 Can prostate cancer treatment preserve quality of life without sacrificing outcomes?

Thank you Dr. Robert Siemens for talking about the article, "Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points."

🔗 Click to read the full article: https://bit.ly/4cSfodY

In this Editorial Comment, the authors describe how a combined B‑cell/CD8 T‑cell biomarker (B8T) can enhance ctDNA‑based...
03/16/2026

In this Editorial Comment, the authors describe how a combined B‑cell/CD8 T‑cell biomarker (B8T) can enhance ctDNA‑based prediction of survival and immunotherapy benefit in high‑risk muscle‑invasive urothelial carcinoma. High B8T expression correlated with better outcomes, and certain B8T patterns predicted response to atezolizumab—especially in ctDNA‑positive patients—highlighting the growing role of B‑cell–focused biomarkers in refining treatment selection.

🔗 Click to read more: https://bit.ly/3OLcYUr

Address

1000 Corporate Boulevard
Linthicum, MD

Website

Alerts

Be the first to know and let us send you an email when The Journal of Urology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to The Journal of Urology:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category